Immunoproliferative Disorders clinical trials
The registry lists 60 studies for Immunoproliferative Disorders across more than 10 countries. 9 are recruiting or about to start. 1 of them are mainly about Immunoproliferative Disorders (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-06. Counting its 57 narrower conditions too, such as Multiple Myeloma: 15,227 studies, 3,345 open.
Get an email when these change. Save the Immunoproliferative Disorders studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Seagen Inc. (8) · UNC Lineberger Comprehensive Cancer Center (6) · Amgen Research (Munich) GmbH (3) · Center for International Blood and Marrow Transplant Research (2) · miRagen Therapeutics, Inc. (2) · Ariad Pharmaceuticals (2) · Oncternal Therapeutics, Inc (2) · Pfizer (1)
What is being tested here
Drugs under test in Immunoproliferative Disorders studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 5
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 6
- Dec 2026A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study · OriCell Therapeutics Co., Ltd.
- Dec 2026HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis · Center for International Blood and Marrow Transplant Research
- Mar 2027A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma · Kelonia Therapeutics, Inc.
- Jul 2027CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) · Curis, Inc.
- Sep 2027A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Nov 2027Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome · Orca Biosystems, Inc.
Who these studies take
Of the 8 Immunoproliferative Disorders studies recruiting now, 5 (63%) set no upper age limit and 3 (38%) stop at 75 or younger. 1 (13%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (13%) | 1 (13%) |
| 18 | 8 (100%) | 8 (100%) |
| 30 | 7 (88%) | 7 (88%) |
| 40 | 7 (88%) | 7 (88%) |
| 50 | 7 (88%) | 7 (88%) |
| 65 | 7 (88%) | 7 (88%) |
| 75 | 7 (88%) | 7 (88%) |
| 85 | 5 (63%) | 5 (63%) |
Across all 60 studies, recruiting or not: 23% stop at 75 or younger and 8% at 65; 17% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 60. Browse all 60 → or search them.
- CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)RecruitingNCT03328078Phase 1/27 countries
- A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple MyelomaRecruitingNCT07075185Phase 12 countries
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasRecruitingNCT04104776Phase 1/27 countries
- Evaluation of Lymphoma Prognosis and Survivorship in Recently Diagnosed Patients, LEO StudyEnrolling by invitationNCT049967061 country
- Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeRecruitingNCT07216443Phase 21 country
- BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple MyelomaRecruitingNCT06644443Phase 1/21 country
- ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-LymphomaRecruitingNCT04097067Not applicable1 country
- A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL StudyRecruitingNCT06271252Phase 11 country
- ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)RecruitingNCT02670564Phase 41 country
- Administration of T Lymphocytes for Prevention of Relapse of LymphomasActive, not recruitingNCT02663297Phase 11 country
- A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.CompletedNCT05228470Phase 21 country
- DPX-Survivac and Checkpoint Inhibitor in DLBCLCompletedNCT03349450Phase 21 country
- GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALLTerminatedNCT04601584Phase 1/21 country
- HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD ProphylaxisActive, not recruitingNCT06001385Phase 21 country
- Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell LymphomaActive, not recruitingNCT03696784Phase 11 country
- Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHLActive, not recruitingNCT02690545Phase 1/21 country
- Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT02393859Phase 324 countries
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active, not recruitingNCT03162536Phase 1/21 country
- Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCLActive, not recruitingNCT03602157Phase 11 country
- Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALLActive, not recruitingNCT03016377Phase 11 country
- Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromActive, not recruitingNCT02952508Phase 211 countries
- HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation CyclophosphamideActive, not recruitingNCT04904588Phase 21 country
- Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT05804032Phase 32 countries
- A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)CompletedNCT03744676Phase 21 country
- Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL)CompletedNCT055295241 country
- Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell LymphomaCompletedNCT02112526Phase 12 countries
- A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell MalignanciesTerminatedNCT05588440Phase 1/21 country
- Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple MyelomaCompletedNCT01183949Phase 1/21 country
- A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple MyelomaCompletedNCT01063907Phase 1/23 countries
- Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)CompletedNCT02658968Phase 15 countries
- Study Investigating NTLA-5001 in Subjects With Acute Myeloid LeukemiaTerminatedNCT05066165Phase 1/22 countries
- A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT02733042Phase 1/27 countries
- A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell LymphomaWithdrawnNCT05431179Phase 3
- Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple MyelomaStatus unknownNCT04309084Phase 11 country
- A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)CompletedNCT01667133Phase 1/21 country
- SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis FungoidesTerminatedNCT03713320Phase 28 countries
- Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety SwitchNo longer availableNCT035941621 country
- Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell TransplantNo longer availableNCT012000171 country
- Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)CompletedNCT00773747Phase 3
- A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01990534Phase 47 countries
- PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR StudyTerminatedNCT03837457Phase 23 countries
- Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell LymphomaTerminatedNCT02592876Phase 21 country
- Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular LymphomaTerminatedNCT02855359Phase 22 countries
- BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCLTerminatedNCT02366663Phase 31 country
- Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)Status unknownNCT03373019Phase 21 country
- Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant SurvivorsCompletedNCT00701844Not applicable1 country
- Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT01466179Phase 26 countries
- Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaCompletedNCT01471782Phase 1/27 countries
- Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)CompletedNCT01741792Phase 21 country
- A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCLTerminatedNCT00529503Phase 210 countries